The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
Open accessAbstract
BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi combination therapies, there is a need to develop more reliable molecular signatures to better predict response. Here we address the challenge of adapting a gene expression signature predictive of RAS pathway activation, created using fresh frozen (FF) tissues, for use with more widely available formalin fixed paraffin-embedded (FFPE) tissues. METHODS: In this study, we evaluated the translation of an 18-gene RAS pathway signature score from FF to FFPE in 54 CRC cases, using a head-to-head comparison of five technology platforms. FFPE-based technologies included the Affymetrix GeneChip (Affy), NanoString nCounter™ (NanoS), Illumina whole genome RNASeq (RNA-Acc), Illumina targeted RNASeq (t-RNA), and Illumina stranded Total RNA-rRNA-depletion (rRNA). RESULTS: Using Affy_FF as the "gold" standard, initial analysis of the 18-gene RAS scores on all 54 samples shows varying pairwise Spearman correlations, with (1) Affy_FFPE (r = 0.233, p = 0.090); (2) NanoS_FFPE (r = 0.608, p < 0.0001); (3) RNA-Acc_FFPE (r = 0.175, p = 0.21); (4) t-RNA_FFPE (r = -0.237, p = 0.085); (5) and t-RNA (r = -0.012, p = 0.93). These results suggest that only NanoString has successful FF to FFPE translation. The subsequent removal of identified "problematic" samples (n = 15) and genes (n = 2) further improves the correlations of Affy_FF with three of the five technologies: Affy_FFPE (r = 0.672, p < 0.0001); NanoS_FFPE (r = 0.738, p < 0.0001); and RNA-Acc_FFPE (r = 0.483, p = 0.002). CONCLUSIONS: Of the five technology platforms tested, NanoString technology provides a more faithful translation of the RAS pathway gene expression signature from FF to FFPE than the Affymetrix GeneChip and multiple RNASeq technologies. Moreover, NanoString was the most forgiving technology in the analysis of samples with presumably poor RNA quality. Using this approach, the RAS signature score may now be reasonably applied to FFPE clinical samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Flow-chart of the procedure followed in the pre-processing and analysis of the data. Six datasets (1 FF and 5 FFPE, each with 54 samples and 18 genes) underwent quality control procedures before analysis. Thirty-nine [39] “good” samples and 16 “good” genes were retained. Correlation analyses were performed using mean scores from the sample pairs. The predictive ability of the 16–gene set was validated using the Affymetrix FF, Affymetrix FFPE and NanoString gene expression data, by the PAM method](https://figures.cochat.ai/paper-figures/2d9fe1b95c324ae0834d509dc55f120d/adaptation-of-a-ras-pathway-activation-signature-from-ff-to-ffpe-tissues-in-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We recently adapted the 18-gene MEK activation signature from use in fresh frozen CRC samples to more clinically available, archived formalin-fixed, paraffin-embedded (FFPE) tissues [33], as a means to predict RAS/MEK pathway dependence regardless of RAS/RAF mutation status.”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116 · cited 1×
“For the whole transcriptome RNASeq (RNA-Acc and rRNA) platforms, the data was first processed by STAR aligner [30] and cufflinks [31], then the resulting FPKM was log2-transformed and z-score-normalized.”
MethodExploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603 · cited 2×
“Both the 54 Affy_FF and matching Affy_FFPE samples were normalized using the RMA method [26].”
MethodComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930 · cited 1×
“The nearest shrunken centroids algorithm [33] was employed in predicting the mutation type of a sample, based on the gene expression profiles of the 16 genes from the 18-gene RAS signature.”
MethodPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“It has been recently reported that mutations in BRAF and NRAS that also activate the RAS pathway may account for EGFRi therapy resistance in some of the wild-type KRAS CRCs [7, 10, 12, 14].”
BackgroundKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“It has been recently reported that mutations in BRAF and NRAS that also activate the RAS pathway may account for EGFRi therapy resistance in some of the wild-type KRAS CRCs [7, 10, 12, 14].”
Background
Cited by
Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors
Schulert, G. S., Yasin, S., Carey, B., Chalk, C., Do, T., Schapiro, A. H., Husami, A., Watts, A., Brunner, H. I., Huggins, J., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41073 · Cited by 212
“FFPE and freshly frozen lung tissue sections (44).”
BackgroundRNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery
Pennock, N. D., Jindal, S., Horton, W. R., Sun, D., Narasimhan, J., Carbone, L., Fei, S. S., Searles, R. P., Harrington, C. A., Burchard, J., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0643-z · Cited by 65
Jovanović, B., Sheng, Q., Seitz, R. S., Lawrence, K. D., Morris, S. W., Thomas, L. R., Hout, D. R., Schweitzer, B. L., Guo, Y. P., Pietenpol, J. A., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3237-1 · Cited by 50
“In a comparison of an 18-gene Ras pathway signature between FF and FFPE using five technologies (Affymetrix GeneChip, NanoString, Illumina RNA-Seq, Illumina targeted RNA –seq and Illumina rRNA-depleted stranded RNA-seq), the investigators show that only the NanoString technology provides an acceptable translation of t…”
MethodPark, S., Hwang, C. Y., Cho, S., Lee, D., Gong, J., Lee, S., Nam, S., & Cho, K. (2019) · FEBS Journal · doi:10.1111/febs.14773 · Cited by 48
Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients
Morrison, C. M., Weterings, E., Mahadevan, D., Sanan, A., Weinand, M. E., & Stea, B. (2021) · Cancers · doi:10.3390/cancers13215358 · Cited by 35
Metadata
- Authors
- Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J.
- Affiliations
- University of South Carolina Upstate (US)
- Covance (United States) (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- Venue
- BMC Medical Genomics
- Published
- 2016-10-19
- Volume
- 9
- Issue
- 1
- Pages
- 65-65
- ISSN
- 1755-8794 (ISSN-L)
- PMC
- PMC5069826
- OpenAlex
- W2536826816
- Cited by
- 25
- References
- 44
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 9 · 2018: 2 · 2017: 2
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Medical Genomics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SU+ Digital Repository (Strathmore University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (U01CA157960)
- The Burroughs Wellcome Fund (1015192)
- Simons Foundation (282714)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, KRAS mutation, formalin-fixed paraffin-embedded tissue, fresh frozen tissue, EGFR inhibitor resistance, predictive biomarkers, NanoString nCounter, Affymetrix GeneChip, RNA sequencing, targeted RNA sequencing, platform comparison
- MeSH terms
- Formaldehyde, Humans, Mutation, Colorectal Neoplasms, Signal Transduction, Paraffin Embedding, Tissue Fixation, ras Proteins, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. https://app.cochat.ai/papers/10.1186/s12920-016-0225-2
- The paper
- Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016). Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Medical Genomics. https://doi.org/10.1186/s12920-016-0225-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.